Haemodynamic monitoring as an opportunity for tailoring diuretics and guideline‐directed medical therapy in heart failure.

Guideline-directed medical therapy (GDMT) forms the cornerstone of HFrEF therapy and currently consists of four drug classes: renin-angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i). The "risk-treatment paradox" is notably pronounced in this subset of patients, arising from a wide range of factors attributed to the patient, healthcare system, and healthcare provider.[5] For instance, assumed intolerance or a disproportionate fear of side effects can limit GDMT implementation in frail patients who are most in need of effective medical therapy. Haemodynamic monitoring as an opportunity for tailoring diuretics and guideline-directed medical therapy in heart failure. [Extracted from the article]